Literature DB >> 10772635

In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin.

M B Fisher1, K Campanale, B L Ackermann, M VandenBranden, S A Wrighton.   

Abstract

The UDP-glucuronosyltransferases (UGTs) are a superfamily of membrane-bound enzymes whose active site is localized inside the endoplasmic reticulum. Glucuronidation using human liver microsomes has traditionally involved disruption of the membrane barrier, usually by detergent treatment, to attain maximal enzyme activity. The goals of the current work were to develop a universal method to glucuronidate xenobiotic substrates using microsomes, and to apply this method to sequential oxidation-glucuronidation reactions. Three assays of UGT catalytic activity estradiol-3-glucuronidation, acetaminophen-O-glucuronidation, and morphine-3-glucuronidation, which are relatively selective probes for human UGT1A1, 1A6, and 2B7 isoforms, respectively, were developed. Treatment of microsomes with the pore-forming peptide alamethicin (50 microg/mg protein) resulted in conjugation rates 2 to 3 times the rates observed with untreated microsomes. Addition of physiological concentrations of Mg(2+) to the alamethicin-treated microsomes yielded rates that were 4 to 7 times the rates with untreated microsomes. Optimized assay conditions were found not to detrimentally affect cytochrome P450 activity as determined by effects on testosterone 6beta-hydroxylation and 7-ethoxycoumarin deethylation. Formation of estradiol-3-glucuronide displayed atypical kinetics, and data best fit the Hill equation, yielding apparent kinetic parameters of K(m)(app) = 0.017 mM, V(max)(app) = 0.4 nmol/mg/min, and n = 1.8. Formation of acetaminophen-O-glucuronide also best fit the Hill equation, with K(m)(app) = 4 mM, V(max)(app) = 1.5 nmol/mg/min, and n = 1.4. Alternatively, morphine-3-glucuronide formation displayed Michaelis-Menten kinetics, with K(m)(app) = 2 mM and V(max)(app) = 2. 5 nmol/mg/min. Finally, alamethicin treatment of microsomes was found to be effective in facilitating the sequential oxidation-glucuronidation of 7-ethoxycoumarin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10772635

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  52 in total

1.  Metabolic assessment in liver microsomes by co-activating cytochrome P450s and UDP-glycosyltransferases.

Authors:  Z Yan; G W Caldwell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jul-Sep       Impact factor: 2.441

2.  In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.

Authors:  N H Schebb; B Franze; R Maul; A Ranganathan; B D Hammock
Journal:  Drug Metab Dispos       Date:  2011-09-27       Impact factor: 3.922

3.  Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.

Authors:  Katherine L Gill; J Brian Houston; Aleksandra Galetin
Journal:  Drug Metab Dispos       Date:  2012-01-24       Impact factor: 3.922

4.  Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations.

Authors:  Michael A Mohutsky; Jenny Y Chien; Barbara J Ring; Steven A Wrighton
Journal:  Pharm Res       Date:  2006-03-24       Impact factor: 4.200

Review 5.  Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.

Authors:  Timothy W Harper; Patrick J Brassil
Journal:  AAPS J       Date:  2008-04-05       Impact factor: 4.009

6.  Measurement of kinetic parameters for biotransformation of polycyclic aromatic hydrocarbons by trout liver S9 fractions: Implications for bioaccumulation assessment.

Authors:  John W Nichols; Melanie A Ladd; Patrick N Fitzsimmons
Journal:  Appl In Vitro Toxicol       Date:  2018

7.  Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites.

Authors:  Jin Zhou; Timothy S Tracy; Rory P Remmel
Journal:  Drug Metab Dispos       Date:  2009-12-09       Impact factor: 3.922

8.  Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases.

Authors:  Nenad Manevski; Mika Kurkela; Camilla Höglund; Timo Mauriala; Michael H Court; Jari Yli-Kauhaluoma; Moshe Finel
Journal:  Drug Metab Dispos       Date:  2009-12-10       Impact factor: 3.922

9.  Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.

Authors:  Helen E Cubitt; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2009-01-31       Impact factor: 4.200

10.  Use of physiologically based biokinetic (PBBK) modeling to study estragole bioactivation and detoxification in humans as compared with male rats.

Authors:  Ans Punt; Alicia Paini; Marelle G Boersma; Andreas P Freidig; Thierry Delatour; Gabriele Scholz; Benoît Schilter; Peter J van Bladeren; Ivonne M C M Rietjens
Journal:  Toxicol Sci       Date:  2009-05-15       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.